Literature DB >> 29207716

Expression of p16INK4A Protein in Cervical Intraepithelial Neoplasia and Invasive Carcinoma of Uterine Cervix.

Vatsala Kishore1, Anuradha G Patil2.   

Abstract

INTRODUCTION: Cervical cancer still ranks as the most frequent cancer among women in India. Infection with Human Papilloma Virus (HPV) results in precancerous lesions and invasive cervical cancer. Interaction of HPV oncogenic proteins with cellular regulatory proteins leads to upregulation of p16INK4A, a cyclin dependent kinase inhibitor. Therefore, p16INK4A overexpression is a surrogate biomarker of HPV infection making it useful in evaluating HPV associated premalignant and malignant lesions of gynaecological tract. AIM: This study was conducted to evaluate the usefulness of p16INK4A as a biomarker in dysplastic and malignant alteration of cervical epithelium.Materials and
Methods: A total of 57 specimens diagnosed histopathologically as cervical dysplasia or malignancy were included in this prospective study of two year duration. Immunohistochemical (IHC) study of p16INK4A expression was performed on normal cervical tissue samples, Cervical Intraepithelial Neoplasia (CIN) 1, CIN 2, CIN 3, squamous cell carcinoma, adenocarcinoma. Expression was scored by two methods. One was simple positive versus negative p16INK4A staining and the other method was a semi-quantitative IHC scoring (0 to 8 points) according to the intensity of staining and the proportion of stained cells. The collected data was entered in excel sheet and analysed using Statistical Package For Social Science (SPSS) 16.0 software and the descriptive statistics, Chi-square test. The p-value of <0.05 was considered statistically significant.
RESULTS: Nuclear and/or cytoplasmic p16INK4A immunoreactivity was absent in normal cervical tissue, while immunopositivity was 25% in CIN 1, 50% in CIN 2, 75% in CIN 3, 75% and 100% in squamous cell carcinoma and adenocarcinoma respectively. All normal cervical samples had low scores (0 to 2 points), while number of cases with high scores was proportional to the degree of cervical dysplasia or invasive carcinoma. p16INK4A immunostaining with higher expression (score>5) was observed in 75% cases of carcinoma cervix.
CONCLUSION: IHC expression of p16INK4A is related to degree of histological dysplasia and malignancy, suggesting its prognostic and predictive value in the management of cervical cancers.

Entities:  

Keywords:  Dysplasia; Human papilloma virus; Kinase inhibitor

Year:  2017        PMID: 29207716      PMCID: PMC5713738          DOI: 10.7860/JCDR/2017/29394.10644

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  16 in total

1.  p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer.

Authors:  N Murphy; M Ring; C C B B Heffron; B King; A G Killalea; C Hughes; C M Martin; E McGuinness; O Sheils; J J O'Leary
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

2.  Human papillomavirus genotyping and p16INK4a expression in cervical intraepithelial neoplasia of adolescents.

Authors:  Lulin Hu; Ming Guo; Zhi He; Justin Thornton; Larry S McDaniel; Michael D Hughson
Journal:  Mod Pathol       Date:  2005-02       Impact factor: 7.842

3.  P16INK4A and MIB-1: an immunohistochemical expression in preneoplasia and neoplasia of the cervix.

Authors:  Supriya Srivastava
Journal:  Indian J Pathol Microbiol       Date:  2010 Jul-Sep       Impact factor: 0.740

Review 4.  Human papillomavirus infection, cancer & therapy.

Authors:  Helena Sterlinko Grm; Martina Bergant; Lawrence Banks
Journal:  Indian J Med Res       Date:  2009-09       Impact factor: 2.375

5.  Epidemiologic classification of human papillomavirus types associated with cervical cancer.

Authors:  Nubia Muñoz; F Xavier Bosch; Silvia de Sanjosé; Rolando Herrero; Xavier Castellsagué; Keerti V Shah; Peter J F Snijders; Chris J L M Meijer
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

6.  Protein p 16INK4A expression in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of uterine cervix.

Authors:  Ruchi Gupta; Radhika Srinivasan; Raje Nijhawan; Vanita Suri; Radha Uppal
Journal:  Indian J Pathol Microbiol       Date:  2010 Jan-Mar       Impact factor: 0.740

7.  p16INK4A as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and ThinPrep smears.

Authors:  N Murphy; M Ring; A G Killalea; V Uhlmann; M O'Donovan; F Mulcahy; M Turner; E McGuinness; M Griffin; C Martin; O Sheils; J J O'Leary
Journal:  J Clin Pathol       Date:  2003-01       Impact factor: 3.411

8.  p16 as a diagnostic marker of cervical neoplasia: a tissue microarray study of 796 archival specimens.

Authors:  Iana Lesnikova; Marianne Lidang; Stephen Hamilton-Dutoit; Jørn Koch
Journal:  Diagn Pathol       Date:  2009-07-09       Impact factor: 2.644

9.  Histological cell type and DNA value in the prognosis of squamous cell cancer of uterine cervix.

Authors:  A B Ng; N B Atkin
Journal:  Br J Cancer       Date:  1973-10       Impact factor: 7.640

10.  Protein p16 as a marker of dysplastic and neoplastic alterations in cervical epithelial cells.

Authors:  Galina Volgareva; Larisa Zavalishina; Yulia Andreeva; Georgy Frank; Ella Krutikova; Darya Golovina; Alexander Bliev; Dimitry Spitkovsky; Valeriya Ermilova; Fjodor Kisseljov
Journal:  BMC Cancer       Date:  2004-08-31       Impact factor: 4.430

View more
  2 in total

1.  Expression of GMFB in High-Grade Cervical Intraepithelial Neoplasia and Its Role in Cervical Cancer.

Authors:  Jun Tian; Jianqing Wang; Yinxiu Chi; Zhongbao Han; Dongliang Zhang; Hu Zhang
Journal:  Comput Math Methods Med       Date:  2022-09-22       Impact factor: 2.809

2.  Significance of Combined Analysis of High-Risk Human Papillomaviruses Polymerized Chain Reaction Analysis and Immunohistochemical Expression of p16INK4A in Cervical Cancer in a Cohort of South-Indian Population.

Authors:  Thathapudi Sujatha; Surekha Mullapudi Venkata; Erukkambattu Jayashankar; Uday Kumar Putcha; Sandeep Kumar Koturu; Triveni Bhopal; Krishnaveni Neelala; Sanjeeva Kumari Chinta; Reji Manjunathan
Journal:  Cureus       Date:  2022-09-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.